Cytek® Biosciences Gains Approval for 1-Laser and 2-Laser 6-Color TBNK Reagents for Clinical Use in China

Cytek® Biosciences Gains Approval for 1-Laser and 2-Laser 6-Color TBNK Reagents for Clinical Use in China

By, Admin 30 May 2024

Overview

Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received approval from the China National Medical Products Administration (NMPA) for clinical diagnostic use on the Cytek® Northern Lights™-Clinical (NL-CLC™) cell analysis systems. This marks the first clinical approval for a 1-laser based 6-color TBNK assay supported by Full Spectrum Profiling™ (FSP™) technology.

TBNK Analysis

  • TBNK analysis is crucial for evaluating and monitoring the immune system's status in various medical conditions. 
  • These reagents allow for the identification and quantification of key lymphocyte subsets, aiding in diagnosing and monitoring immunodeficiencies, autoimmune diseases, infectious diseases, and cancers. 
  • By providing insights into the immune system's composition, function, and therapeutic response, TBNK reagents help guide targeted treatment decisions and ongoing patient management.

Words from CEO: Cytek Biosciences

  • “We are committed to delivering innovative and powerful solutions that enable clinicians to rapidly and efficiently gain deep insights into patient diagnoses,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. 
  • “Obtaining NMPA clearance is a significant milestone that validates the safety and efficacy of our TBNK reagents. This approval strengthens our market presence in China, opens up new opportunities, and enhances our competitive edge.”

Assay Validation

  • The assay is validated on the Cytek Northern Lights-Clinical (NL-CLC) cell analysis systems, ensuring optimal performance in a multicolor environment. 
  • Furthermore, the use of an on-board volumetric meter for absolute cell counts on NL-CLC instruments eliminates the need for counting beads, thereby reducing testing costs. 
  • Cytek is also seeking regulatory approvals in other regions to expand the clinical availability of its cell analysis solutions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!